van der Linden Naomi, Bongers Mathilda L, Coupé Veerle M H, Smit Egbert F, Groen Harry J M, Welling Alle, Schramel Franz M N H, Uyl-de Groot Carin A
Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia.
Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands.
Clin Lung Cancer. 2017 Sep;18(5):e341-e347. doi: 10.1016/j.cllc.2015.11.011. Epub 2015 Nov 30.
The aims of this study are to analyze differences in survival between academic and non-academic hospitals and to provide insight into treatment patterns for non-small cell lung cancer (NSCLC). Results show the state of NSCLC survival and care in the Netherlands.
The Netherlands Cancer Registry provided data on NSCLC survival for all Dutch hospitals. We used the Kaplan-Meier estimate to calculate median survival time by hospital type and a Cox proportional hazards model to estimate the relative risk of mortality (expressed as hazard ratios) for patients diagnosed in academic versus non-academic hospitals, with adjustment for age, gender, and tumor histology, and stratifying for disease stage. Data on treatment patterns in Dutch hospitals was obtained from 4 hospitals (2 academic, 2 non-academic). A random sample of patients diagnosed with NSCLC from January 2009 until January 2011 was identified through hospital databases. Data was obtained on patient characteristics, tumor characteristics, and treatments.
The Cox proportional hazards model shows a significantly decreased hazard ratio of mortality for patients diagnosed in academic hospitals, as opposed to patients diagnosed in non-academic hospitals. This is specifically true for primary radiotherapy patients and patients who receive systemic treatment for non-metastasized NSCLC.
Patients diagnosed in academic hospitals have better median overall survival than patients diagnosed in non-academic hospitals, especially for patients treated with radiotherapy, systemic treatment, or combinations. This difference may be caused by residual confounding since the estimates were not adjusted for performance status. A wide variety of surgical, radiotherapeutic, and systemic treatments is prescribed.
本研究旨在分析学术型医院与非学术型医院在生存率方面的差异,并深入了解非小细胞肺癌(NSCLC)的治疗模式。结果显示了荷兰NSCLC的生存和治疗状况。
荷兰癌症登记处提供了所有荷兰医院NSCLC生存数据。我们使用Kaplan-Meier估计法按医院类型计算中位生存时间,并使用Cox比例风险模型估计在学术型医院与非学术型医院确诊患者的死亡相对风险(以风险比表示),同时对年龄、性别和肿瘤组织学进行调整,并按疾病分期分层。荷兰医院的治疗模式数据来自4家医院(2家学术型,2家非学术型)。通过医院数据库确定了2009年1月至2011年1月期间被诊断为NSCLC的患者的随机样本。获取了患者特征、肿瘤特征和治疗的数据。
Cox比例风险模型显示,与在非学术型医院确诊的患者相比,在学术型医院确诊的患者的死亡风险比显著降低。对于接受原发性放疗的患者和接受非转移性NSCLC全身治疗的患者尤其如此。
在学术型医院确诊的患者的中位总生存期优于在非学术型医院确诊的患者,特别是对于接受放疗、全身治疗或联合治疗的患者。由于估计未根据体能状态进行调整,这种差异可能是由残余混杂因素导致的。各种手术、放射治疗和全身治疗方法都有应用。